US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Major Depressive Disorder · Migraine · AXSM
Axsome Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Axsome Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
Development asset linked to Axsome Therapeutics in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
Development asset linked to Axsome Therapeutics in public FDA and regional records. Molecular target: Sodium-dependent noradrenaline transporter.
Development asset linked to Axsome Therapeutics in public FDA and regional records. Mechanism: Serotonin 1b (5-HT1b) receptor agonist.
US regulatory status: approved.
US regulatory status: approved. Mechanism: Unknown.